Amgen has launched a late-stage program to test the feasibility of switching patients from weekly GLP-1 injections to its own ...

Amgen stock toppled Friday as investors digested its "generally in-line" first-quarter report and expansion in the obesity treatment space.

By Deena Beasley April 30 (Reuters) - Amgen on Thursday said its first-quarter product sales rose 4%, helped by demand for ...

The FDA has renewed calls for Amgen’s Tavneos to be pulled from the market, saying it has discovered new evidence that study ...

Earlier this year, when the FDA asked Amgen to pull its rare disease drug Tavneos from the market, the California drugmaker ...

Delve into the pipeline strategy of major biotech Amgen, which is increasingly diversifying its growth engines.

Amgen Inc (AMGN) reports a robust 4% growth in product sales, driven by key growth drivers, while navigating patent expirations and increased competition.

Amgen announced 52-week results from a phase 2 trial with its weight-management candidate, MariTide. The results Amgen posted don't appear very competitive with Eli Lilly's weight management drug, ...

Biotech giant Amgen on April 22 announced the retirement of David Reese, executive vice president and chief technology officer, who has been with the Thousand Oaks-based company for 21 years. Reese, ...

The Food and Drug Administration (FDA) is set to pilot test real-time clinical trials in the hopes of expediting results and ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The U.S. Food and Drug Administration's Center ​for Drug Evaluation ‌and Research on Monday proposed withdrawing approval of ...